A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells

Process Biochemistry

Volumn 45, Issue 9, 2010, Pages 1537-1542

  Lin, Ching Hsiung ^a,b   Sheu, Gwo Tarng ^c   Lin, Yu Wen ^c   Yeh, Chin Shui ^a   Huang, Yu Hsin ^c   Lai, Yen Chein ^c   Chang, Jan Gowth ^b,e   Ko, Jiunn Liang ^c,d  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AKT; Epidermal growth factor; GMI; Immunomodulatory protein; Rac1 Cdc42

Indexed keywords

AKT; ANGIOGENESIS; ANTICANCER ACTIONS; BIOACTIVE COMPONENTS; BOYDEN CHAMBER; CHEMOPREVENTION; DOSE-DEPENDENT MANNER; EAST ASIA; EPIDERMAL GROWTH FACTORS; GANODERMA; HUMAN EPIDERMAL GROWTH FACTOR; INHIBITORY EFFECT; LUNG CANCER; LUNG CANCER CELLS; LUNG TUMOR; MICROFILAMENTS; MOLECULAR BASIS; MOLECULAR MECHANISM; NON SMALL CELL LUNG CANCER; NOVEL FUNCTIONS; OVER-EXPRESSION; TUMOR INVASION;

BIOACTIVITY; BIOLOGICAL ORGANS; PATHOLOGY; PEPTIDES; PHOSPHORYLATION;

TUMORS;

BASIDIOMYCOTA; GANODERMA; GANODERMA MICROSPORUM; MICROSPORUM;

EID: 77955053878     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2010.06.006     Document Type: Article

References (34)

1. Hirsch F.R., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21(20):3798-3807.
2. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354.
3. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4(5):361-370.
4. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
5. Pawson T. Protein modules and signalling networks. Nature 1995, 373(6515):573-580.
6. Gorgoulis V., et al. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 1992, 12(4):1183-1187.
7. Jinn T.R., et al. Functional expression of FIP-gts, a fungal immunomodulatory protein from Ganoderma tsugae in Sf21 insect cells. Biosci Biotechnol Biochem 2006, 70(11):2627-2634.
8. Boh B., et al. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007, 13:265-301.
9. Hsu H.C., et al. Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J 1997, 323(Pt 2):557-565.
10. Ko J.L., et al. A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. Eur J Biochem 1995, 228(2):244-249.
11. Xuanwei Z., et al. Identification of medicinal Ganoderma species based on PCR with specific primers and PCR-RFLP. Planta Med 2008, 74(2):197-200.
12. Liao C.H., et al. Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from Ganoderma tsugae in A549 human lung adenocarcinoma cell line. Mol Carcinog 2006, 45(4):220-229.
13. Liao C.H., et al. Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food Chem Toxicol 2008, 46(5):1851-1859.
14. Lu Z., et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4(6):499-515.
15. Jaramillo M.L., et al. Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol Ther 2008, 7(4):557-568.
16. Chung B.M., et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 2009, 28(16):1821-1832.
17. Lin Y.L., et al. An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. J Leukoc Biol 2009, 86(4):877-889.
18. Al-Samarrai T.H., Schmid J. A simple method for extraction of fungal genomic DNA. Lett Appl Microbiol 2000, 30(1):53-56.
19. Binker M.G., et al. EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. Biochem Biophys Res Commun 2009, 379(2):445-450.
20. Lee W.J., et al. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 2008, 226(2):178-191.
21. Shih Y.W., et al. Alpha-tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: effect on metastasis. Food Chem Toxicol 2009, 47(8):1985-1995.
22. Broadbelt N.V., et al. Pressure activates epidermal growth factor receptor leading to the induction of iNOS via NFkappaB and STAT3 in human proximal tubule cells. Am J Physiol Renal Physiol 2009, 297(1):F114-F124.
23. Denys H., et al. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett 2008, 266(2):263-274.
24. Sun M., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009, 15(15):4829-4837.
25. Jiang Q., et al. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2006, 22(2):93-102.
26. Zhou W., Grandis J.R., Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer 2006, 95(2):164-171.
27. Marcoux N., Vuori K. EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2. Oncogene 2003, 22(38):6100-6106.
28. Chou J., et al. Directional motility induced by epidermal growth factor requires Cdc42. Exp Cell Res 2003, 287(1):47-56.
29. Scagliotti G.V., et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004, 10(12 Pt 2):4227s-4232s.
30. Ho C., Laskin J. EGFR-directed therapies to treat non-small-cell lung cancer. Expert Opin Invest Drugs 2009, 18(8):1133-1145.
31. Friedrich M.J. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. J Natl Cancer Inst 2009, 101(15):1039-1041.
32. Ozawa S., et al. Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci 2009.
33. Reck M. Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2009, 9(4):401-412.
34. Gerber D.E. EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res 2008, 69(6):359-372.